Clerk of the House of Representatives	Secretary of the Senate
Legislative Resource Center	Office of Public Records
B-106 Cannon Building	232 Hart Building
Washington, DC 20515	Washington, DC 20510

Secretary of the Senate
Received: Aug 14, 2007

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

NATL PSORIASIS FOUNDATION

2. Address:
6600 SW 92nd Ave. Ste. 300, Portland, OR 97223-7195

3. Principal place of business (if different from line 2):

4. Contact Name: ALYSSA BROWN
Telephone: 5035468407
E-mail (optional): abrown@psoriasis.org

Senate ID #: 314658-12
House ID #:

7. Client Name: ☒ Self

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): ☒ **OR** Year End (July 1 - December 31): ☐

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than $10,000: ☐

$10,000 or more: ☐ => Income (nearest $20,000):_____

Provide a good faith estimate, rounded to the nearest $20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than $10,000: ☐

$10,000 or more: ☒ => Expenses (nearest $20,000): 180,000.00

14. Reporting Method.
Check box to indicate expense accounting method. See instructions for description of options.

☐ **Method A.** Reporting amounts using LDA definitions only
☒ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H.R.3043, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics S.1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
Natl Institutes of Health (NIH)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: .
Covered Official Position (if applicable): N/A
Name: BROWN, ALYSSA
Covered Official Position (if applicable): N/A
Name: RITTENBERG, SHEILA
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 104. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE ▮ Directs the HHS Secretary to enter into a contract with the Institute of Medicine (IOM) to conduct a study to evaluate and make recommendations to address the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis; (2) The payment structures, such as deductibles and co-payments, amounts and duration of the coverage and payments under health plans and their adequacy to cover the costs of providing ongoing care to patients with psoriasis and psoriatic arthritis; (3) Health plan and insurer coverage policies and practices and their impact on patient access to the best regimen and most appropriate care for their particular disease state. Access to care for people with psoriasis and psoriatic arthritis H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007

17. House(s) of Congress and Federal agencies contacted:
Agency for Health Care Policy & Research
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: .
Covered Official Position (if applicable): N/A
Name: BROWN, ALYSSA
Covered Official Position (if applicable): N/A
Name: RITTENBERG, SHEILA
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

S.Res.116, A resolution designating May 2007 as "National Autoimmune Diseases Awareness Month" and supporting efforts to increase awareness of autoimmune diseases and increase funding for autoimmune disease research. H.Res.258, Expressing the sense of the House of Representatives that there should be established a National Autoimmune Diseases Awareness Month and for other purposes H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 101. EXPANSION OF BIOMEDICAL RESEARCH | Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research on psoriasis and psoriatic arthritis. | Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and offices with respect to psoriasis and psoriatic arthritis research. Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY | Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS SUMMIT | Directs the Department of Health and Human Services (HHS) to convene a summit of researchers, public health professionals, patient advocacy organizations, academic institutions, and Federal and State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, and other federal agencies whose work involves psoriasis and psoriatic arthritis related co-morbidities. | Requires a report to Congress | not later than 180 days after the convening of summit. H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007

17. House(s) of Congress and Federal agencies contacted:
Centers For Disease Control & Prevention (CDC)
HOUSE OF REPRESENTATIVES
Natl Institutes of Health (NIH)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: .
Covered Official Position (if applicable): N/A
Name: BROWN, ALYSSA
Covered Official Position (if applicable): N/A
Name: RITTENBERG, SHEILA
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

Signature: ON FILE Date: Aug 14, 2007

Printed Name and Title: ALYSSA L BROWN, ADVOCACY COORDINATOR -

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Aug 14, 2007

Printed Name and Title: -